CA2491427A1 - Compositions et procedes pour traitement therapeutique - Google Patents

Compositions et procedes pour traitement therapeutique Download PDF

Info

Publication number
CA2491427A1
CA2491427A1 CA002491427A CA2491427A CA2491427A1 CA 2491427 A1 CA2491427 A1 CA 2491427A1 CA 002491427 A CA002491427 A CA 002491427A CA 2491427 A CA2491427 A CA 2491427A CA 2491427 A1 CA2491427 A1 CA 2491427A1
Authority
CA
Canada
Prior art keywords
composition
agent
antibody
fragment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002491427A
Other languages
English (en)
Inventor
Janette Lazarovits
Abraham Nimrod
Hagit Hoch-Mar-Chaim
Avigdor Levanon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2491427A1 publication Critical patent/CA2491427A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions faisant intervenir un agent et un anticorps, ou un fragment dudit anticorps. Dans ces compositions, les agents, notamment des agents anti-canc~reux, anti-m~tastases, anti-leuc~miques, anti-maladies, anti-adh~rents, anti-thromboses, anti-rest~noses, anti-maladies auto-immunes, anti-aggr~gants, anti-bact~riens, anti-viraux et anti-inflammatoires, peuvent Útre complex~s ou combin~s aux anticorps ou conjugu~s ~ ceux-ci, ou ~ des fragments de ceux-ci. En outre, l'agent et/ou l'anticorps, ou le fragment de celui-ci, peut Útre pr~sent dans la composition ~ une quantit~ sous-clinique, qui est une quantit~ inf~rieure ~ la quantit~ de l'agent g~n~ralement efficace sur le plan clinique lorsque cet agent est administr~ seul. De pr~f~rence, dans ces compositions, l'agent est un agent anthracycline ou un d~riv~ de celui-ci, par exemple de la doxorubicine (adriamycin) ou un d~riv~ de celle-ci.
CA002491427A 2002-07-01 2003-06-30 Compositions et procedes pour traitement therapeutique Abandoned CA2491427A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18902502A 2002-07-01 2002-07-01
US10/189,025 2002-07-01
PCT/US2003/020604 WO2004002528A1 (fr) 2002-07-01 2003-06-30 Compositions et procedes pour traitement therapeutique

Publications (1)

Publication Number Publication Date
CA2491427A1 true CA2491427A1 (fr) 2004-01-08

Family

ID=29999592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002491427A Abandoned CA2491427A1 (fr) 2002-07-01 2003-06-30 Compositions et procedes pour traitement therapeutique

Country Status (12)

Country Link
EP (1) EP1551452A4 (fr)
JP (1) JP2005534679A (fr)
KR (1) KR20050059001A (fr)
CN (1) CN1678348A (fr)
AU (1) AU2003279657A1 (fr)
BR (1) BR0312484A (fr)
CA (1) CA2491427A1 (fr)
IL (1) IL166062A0 (fr)
MX (1) MXPA05000271A (fr)
PL (1) PL374431A1 (fr)
RU (1) RU2005101622A (fr)
WO (1) WO2004002528A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003144A2 (fr) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Anticorps qui se lient specifiquement a reg iv
AU2005229492A1 (en) * 2004-03-30 2005-10-13 Rigshospitalet Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
DK1737428T3 (en) * 2004-03-31 2017-10-09 Univ Utah Res Found MACROMOLECULAR ADMINISTRATION SYSTEMS FOR NON-INVASIVE IMAGING, EVALUATION AND TREATMENT OF ARTHRITIS AND OTHER INFLAMMATORY DISEASES
AU2006294663B2 (en) 2005-09-26 2012-03-22 Medarex, Inc. Human monoclonal antibodies to CD70
EP2373343B1 (fr) * 2008-12-19 2015-02-11 Philogen S.p.A. Immunocytokines pour thérapie tumorale avec agents chimiothérapiques
CN106659784B (zh) 2014-07-08 2022-03-29 桑福德伯纳姆医学研究所 Psgl-1调控剂及其用途
MX2018008144A (es) * 2016-01-08 2018-11-09 Bioalliance Cv Anticuerpos tetravalentes anti ligando-1 de glicoproteina p-selectina (psgl-1) y usos de estos.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05244987A (ja) * 1992-02-28 1993-09-24 Unitika Ltd 抗硫酸化チロシン抗体，その製造方法及び抗硫酸化チロシンモノクローナル抗体を産生するハイブリドーマ
US6106834A (en) * 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
DE69904831T2 (de) * 1998-07-13 2003-11-06 Univ Texas Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
CA2347119A1 (fr) * 1998-10-30 2000-05-11 Genetics Institute, Inc. Inhibition de la differentiation des lymphocytes t cytotoxiques par des antagonistes du ligand de p-selectine (psgl)
AU2000248423A1 (en) * 2000-05-11 2001-11-20 National Tsing Hua University Compositions and methods for induction of active autoimmunity
JP2003533490A (ja) * 2000-05-15 2003-11-11 フアルマシア・イタリア・エツセ・ピー・アー 抗腫瘍剤としてのアロマターゼ阻害剤および抗−ｈｅｒ２モノクローナル抗体
CA2433225A1 (fr) * 2000-12-29 2002-07-11 Bio-Technology General, Inc. Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes
CN100374456C (zh) * 2000-12-29 2008-03-12 萨文特医药公司 用于选择性癌症治疗的特异性人抗体

Also Published As

Publication number Publication date
CN1678348A (zh) 2005-10-05
EP1551452A1 (fr) 2005-07-13
EP1551452A4 (fr) 2006-08-30
JP2005534679A (ja) 2005-11-17
AU2003279657A1 (en) 2004-01-19
RU2005101622A (ru) 2006-01-27
IL166062A0 (en) 2006-01-15
WO2004002528A1 (fr) 2004-01-08
MXPA05000271A (es) 2005-03-31
PL374431A1 (en) 2005-10-17
BR0312484A (pt) 2008-01-08
KR20050059001A (ko) 2005-06-17
WO2004002528A9 (fr) 2004-11-18

Similar Documents

Publication Publication Date Title
US20040002450A1 (en) Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20090220486A1 (en) Antibodies and uses thereof
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20070149768A1 (en) Specific human antibodies for selective cancer therapy
JP2020509737A (ja) 新規な組換え型二機能性融合タンパク質、その調製方法および用途
US20040202665A1 (en) Compositions and methods for therapeutic treatment
EP1406930A2 (fr) Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes
AU2002246737B2 (en) Specific human antibodies for selective cancer therapy
JP2005503756A5 (fr)
AU2002246737A1 (en) Specific human antibodies for selective cancer therapy
WO2004003166A2 (fr) Anticorps et leurs applications
CA2491427A1 (fr) Compositions et procedes pour traitement therapeutique
US20050152906A1 (en) Specific human antibodies
US20080274100A1 (en) Antibodies and uses thereof
CA2531283A1 (fr) Anticorps humains specifiques
WO2005010153A2 (fr) Anticorps et utilisations de ceux-ci
US20040208877A1 (en) Antibodies and uses thereof
AU2002246738A1 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued